Literature DB >> 31289982

Multiparametric prostatic MRI should not be the only method to decide re-biopsy in the patients who had a negative prostatic biopsy.

Ali Atan1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31289982     DOI： 10.1007/s11255-019-02227-w

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  5 in total

Review 1.  Use and assessment of PSA in prostate cancer.

Authors:  Carl K Gjertson; Peter C Albertsen
Journal:  Med Clin North Am       Date:  2011-01       Impact factor: 5.456

2.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 3.  How should prostate specific antigen be interpreted?

Authors:  Ali Atan; Özer Güzel
Journal:  Turk J Urol       Date:  2013-09

Review 4.  The current role of prostate multiparametric magnetic resonance imaging.

Authors:  Olivier Rouviere; Paul Cezar Moldovan
Journal:  Asian J Urol       Date:  2018-12-11

Review 5.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.